Earnings Preview: Bio-Rad Laboratories (BIO) Q2 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Stock Climbs Following the Launch of Four ddPCR Platforms
BIO surges 4% as the Stilla acquisition fuels the launch of four ddPCR systems, expanding to 400K+ assay offerings.
New Strong Sell Stocks for July 10th
BIO, DECK and ELUXY have been added to the Zacks Rank #5 (Strong Sell) List on July 10, 2025.
Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
Bio-Rad witnesses first-quarter top-line decline in its Life Science segment, primarily due to challenges in the academic research market.
Bio-Rad Laboratories, Inc. (BIO) Q1 2025 Earnings Call Transcript
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2025 Earnings Conference Call May 1, 2025 5:30 PM ET Company Participants Edward Chung - Head of Investor Relations Jon DiVincenzo - President and Chief Operating Officer Roop Lakkaraju - Executive Vice President and Chief Financial Officer Norman Schwartz - Chief Executive Officer Conference Call Participants Patrick Donnelly - Citigroup Dan Leonard - UBS Brandon Couillard - Wells Fargo Conor McNamara - RBC Capital Markets Jack Meehan - Nephron Research Operator Ladies and gentlemen, thank you for standing by. My name is Desyree, and I will be your conference operator today.
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.54 per share, beating the Zacks Consensus Estimate of $1.73 per share. This compares to earnings of $2.29 per share a year ago.
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
BIO continues to attract investors' attention due to its robust performance in the ddPCR platform.
Bio-Rad (BIO) International Revenue Performance Explored
Review Bio-Rad's (BIO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
BIO Stock Might Rise Following the Offer to Acquire Stilla
Bio-Rad offers to acquire all equity interests of Stilla Technology. The acquisition is expected to complement Bio-Rad's existing digital PCR portfolio.
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the fourth quarter, primarily driven by an increased demand for quality control and blood typing products.
